PD 166866
Latest Information Update: 04 Feb 2002
Price :
$50 *
At a glance
- Originator Pfizer
- Class Organic chemicals; Pyrimidines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Cancer; Coronary artery restenosis; Transplant rejection
Most Recent Events
- 04 Feb 2002 No-Development-Reported for Atherosclerosis in USA (Unknown route)
- 04 Feb 2002 No-Development-Reported for Cancer in USA (Unknown route)
- 04 Feb 2002 No-Development-Reported for Coronary artery restenosis in USA (Unknown route)